Equity Sector Funds Very High Risk
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | 6.15% | 10.25% | 3.03% | 0.11% | 9.4% | 13.43% | 23.81% | 16.09% | 14.41% | 0% | 19.42% |
| Category returns | 6.83% | 7.45% | 0.03% | -2.3% | 6.38% | 11.92% | 22.96% | 16.06% | 13.74% | 12.95% | N/A |
| Absolute returns | 8.36% | 10.47% | 9.72% | 8.77% | 14.77% | 35.71% | 104.75% | 103.6% | 101.54% | 0% | 323.2% |
| Rank within category | 13 | 3 | 2 | 3 | 3 | 5 | 4 | 4 | 3 | 5 | N/A |
| Total Schemes in Category | 18 | 18 | 17 | 17 | 16 | 14 | 10 | 10 | 9 | 4 | N/A |
| Sector Funds | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Yearly returns | N/A | 6.39% | 73.92% | 26.58% | -11.81% | 34.04% | 39.12% | -3.39% | 10.79% |
| Q1 returns | N/A | 3.8% | -3.02% | -1.2% | -6.93% | -5.11% | 9.57% | -7.66% | -0.99% |
| Q2 returns | N/A | -6.18% | 32.16% | 19.42% | -10.39% | 15.77% | 4.52% | 4.49% | 11.9% |
| Q3 Returns | N/A | 0.87% | 24.08% | 5.75% | 9.17% | 12.02% | 20.04% | -1.08% | N/A |
| Q4 Returns | -3.66% | 8.3% | 9.37% | 1.44% | -3.15% | 8.92% | 1.2% | 1.23% | N/A |
Expense ratio: 1.68%
Inclusive of GST
Exit load
1% on or before 1Y(365D), Nil after 1Y(365D)
| Alpha | 0.0105515 |
| Beta | 0.9655 |
| Sharpe Ratio | 0.351698 |
| Sortino Ratio | 0.795584 |
| R-Squared | 0.9445 |
| Tracking Error | 0.9779 |
| Downside Risk | 16.2988 |
| Std. Deviation (Annualised) | 14.562 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth | 9.18% | 6.67% | -0.99% | -3.59% | 7.1% | 27.02% | 16.23% | 0% | 19.44% | 6,293.14 | 1.87 | 0.39 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | 7.91% | 7.54% | 0.1% | -2.35% | 8.33% | 24.87% | 13.99% | 12.81% | 14.66% | 1,055.53 | 2.28 | 0.35 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | 5.71% | 8.21% | 0.45% | -1.13% | 4.56% | 24.83% | 15.56% | 12.3% | 16.26% | 4,063.64 | 1.93 | 0.37 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth Current | 6.15% | 10.25% | 3.03% | 0.11% | 9.4% | 23.81% | 14.41% | 0% | 19.42% | 2,753.72 | 1.94 | 0.34 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | 4.7% | 6.4% | 1.22% | -1.71% | 5.37% | 22.75% | 12.57% | 0% | 18.41% | 858.87 | 2.30 | 0.33 | Very High |
| Nippon India Pharma Fund - Growth | 5.58% | 6.09% | 0.67% | -3.68% | 4.04% | 22.1% | 13.33% | 14.48% | 19.73% | 7,898.24 | 1.82 | 0.32 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | 6.85% | 5.21% | -3.15% | -4.34% | 2.3% | 22.03% | 13.39% | 12.21% | 11.21% | 1,229.42 | 2.15 | 0.30 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | 8.21% | 4.38% | -0.83% | -4.8% | 4.87% | 21.77% | 13.64% | 0% | 20.1% | 2,891.76 | 1.94 | 0.31 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | 7.33% | 7.14% | -1.96% | -3.4% | 4.69% | 20.94% | 10.57% | 0% | 16.19% | 78.30 | 2.36 | 0.29 | Very High |
| ITI Pharma & Healthcare Fund - Regular Plan - Growth | 8.1% | 8.47% | -2.98% | -5.82% | 0.32% | 19.48% | 0% | 0% | 10.95% | 211.30 | 2.35 | 0.25 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 99.95% |
| Cash & Cash Equivalents and Net Assets | 0.04% | |
| Domestic Mutual Funds Units | 0.01% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 76.12% | |
| Healthcare Services | 22.23% | |
| Chemicals & Petrochemicals | 1.60% | |
| Others | 0.04% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 11.76% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.23% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.12% |
| JB Chemicals & Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.39% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 5.93% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.57% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.44% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.22% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 4.06% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.70% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.51% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 3.28% |
| Aster DM Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.23% |
| Onesource Specialty Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.22% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.16% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.13% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.03% |
| Eris Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.96% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 2.43% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 1.99% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.82% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.75% |
| Narayana Hrudayalaya Ltd. | Healthcare Services | Domestic Equities | 1.31% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.26% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.19% |
| Neogen Chemicals Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.57% |
| Deepak Nitrite Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.54% |
| Sudeep Pharma Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.48% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.46% |
| TREPS | Cash & Cash Equivalents and Net Assets | 0.15% | |
| Wockhardt Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.10% |
| Rubicon Research Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.10% |
| Mirae Asset Liquid Fund-Direct Plan-Growth | Domestic Mutual Funds Units | 0.01% | |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 0.00% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | -0.12% | |
| Total | 100.00% |
RETURNS
It is an Open ended scheme that primarily invests in Sector Funds.
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns.
The scheme benchmark is the BSE Health Care - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 14.77%
3-year: 26.95%
5-year: 15.04%
Top holdings include names such as:
The NAV is around ₹42.32 (approx.) for the Mirae Asset Healthcare Fund - Regular Plan - Growth.
The fund’s AUM is approximately ₹2,939 Cr.
The expense ratio for the Regular Plan is 1.68.
1% on or before 1Y(365D), Nil after 1Y(365D).
Minimum SIP starts at ₹1000.
The minimum lump sum investment is ₹5000. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund managers: Vrijesh Kasera, Tanmay Mehta
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
